About Cote Orphan
Founded in 2012 and based in Silver Spring, United States, Cote Orphan operates as an advisory firm in the pharmaceutical sector, focusing on orphan drug development. Services encompass strategic planning, execution, and navigation of the FDA regulatory process for orphan products. Specialized knowledge is offered in regulatory affairs, drug development, financial metrics, and scientific aspects, with insights into the FDAs perspective to support client pathways.
- Headquarter Silver Spring, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Cote Orphan
Detailed funding history for Cote Orphan
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Cote Orphan
Cote Orphan has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include IQVIA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare advancements are driven by IQVIA through connected intelligence.
|
Locked | Locked | Locked |
Investor details for Cote Orphan
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cote Orphan
Investment portfolio details for Cote Orphan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cote Orphan
Detailed financials for Cote Orphan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cote Orphan Comparisons
Peer comparison for Cote Orphan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cote Orphan
Detailed competitors of Cote Orphan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cote Orphan
Complete news archive for Cote Orphan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cote Orphan
Cote Orphan was founded in 2012.
Cote Orphan is headquartered in Silver Spring, United States. It is registered at Silver Spring, Maryland, United States.
Founded in 2012 and based in Silver Spring, United States, Cote Orphan operates as an advisory firm in the pharmaceutical sector, focusing on orphan drug development. Services encompass strategic planning, execution, and navigation of the FDA regulatory process for orphan products. Specialized knowledge is offered in regulatory affairs, drug development, financial metrics, and scientific aspects, with insights into the FDAs perspective to support client pathways.
Cote Orphan has 1 investor. Key investors include IQVIA.